To print this article, all you need is to be registered or login on Mondaq.com. In December, the SEC filed a complaint against Decision Diagnostics and its CEO, Keith Berman, for falsely claiming the company had developed a finger prick blood test that could instantaneously detect COVID-19. As stated in its complaint, the SEC temporarily suspended trading of Decision Diagnostics securities on April 23, 2020. Now, investors have brought suit as well. Three institutional investors claim the company – which was already in financial distress as a result of alleged misappropriations by Berman – falsely disclosed it was developing an at-home COVID-19 test nearing
Health Care Enforcement Update: Covid-19 Fraud Cases Brought By DOJ And Private Plaintiffs | Mintz - Health Care Viewpoints jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Covid-19 Fraud Cases Brought By DOJ And Private Plaintiffs natlawreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from natlawreview.com Daily Mail and Mail on Sunday newspapers.
Decision Diagnostics Saga Continues as Investors Bring Suit | Proskauer - Corporate Defense and Disputes jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Home / Top News / DECN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – DECN DECN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – DECN NEW YORK, March 14, 2021 (GLOBE NEWSWIRE) WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Decision Diagnostics Corp. (OTC: DECN) between March 3, 2020 and December 17, 2020, inclusive (the “Class Period”), of the important March 16, 2021 lead plaintiff deadline. SO WHAT: If you purchased Decision Diagnostics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
DECN FINAL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Decision Diagnostics Corp. Investors to Secure Counsel Before Important Tuesday Deadline in Securities Class Action – DECN globenewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from globenewswire.com Daily Mail and Mail on Sunday newspapers.
Share this article Share this article NEW YORK, March 12, 2021 /PRNewswire/ Pomerantz LLP announces that a class action lawsuit has been filed against Decision Diagnostics Corporation ( Decision Diagnostics or the Company ) (OTCMKTS: DECN) and certain of its officers. The class action, filed in United States District Court for the Central District of California, and docketed under 21-cv-00418, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Decision Diagnostics securities between March 3, 2020 and December 17, 2020, both dates inclusive (the Class Period ), seeking to recover damages caused by Defendants violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the Exchange Act ) and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.
Who Needs to Know Why It Matters As evidenced in the recently published 2020 Year in Review Report (Report), the Department of Justice’s Fraud Section (Fraud Section) demonstrated its resilience despite the COVID-19 pandemic, as well as its swift response to the evolution of pandemic-induced fraud a trend we expect will continue throughout 2021. As evidenced in the recently published 2020 Year in Review Report (Report), the Department of Justice’s Fraud Section (Fraud Section) demonstrated its resilience despite the COVID-19 pandemic, as well as its swift response to the evolution of pandemic-induced fraud a trend we expect will continue throughout 2021. Several areas of COVID-19-related fraud have emerged throughout the past year the most prominent associated with personal protective equipment (PPE), COVID-19 testing, and the Paycheck Protection Program (PPP) which DOJ has successfully prosecuted under price gouging, health care, and securities fraud laws.
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Decision Diagnostics Corporation of Class Action Lawsuit and Upcoming Deadline prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Press release content from NewMediaWire. The AP news staff was not involved in its creation. DECISION DIAGNOSTICS CLASS ACTION REMINDER Faruqi & Faruqi LLPFebruary 28, 2021 GMT Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $300,000 In Decision Diagnostics Corp. To Contact Him Directly To Discuss Their Options NEW YORK, NY - ( NewMediaWire ) - February 28, 2021 - Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Decision Diagnostics Corp. (“Decision Diagnostics” or the “Company”) (Other OTC:DECN) and reminds investors of the March 16, 2021 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.